Agonistic Anti-CD137 Monoclonal Antibody Treatment Induces CD11b(+)Gr-1(+) Myeloid-derived Suppressor Cells

CD137 (4-1BB/tnfrsf9) has been shown to co-stimulate T cells. However, agonistic anti-CD137 monoclonal antibody (mAb) treatment can suppress CD4(+) T cells, ameliorating autoimmune diseases, whereas it induces activation of CD8(+) T cells, resulting in diverse therapeutic activity in cancer, viral i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jung-Mi, Seo, Jeong-Hwan, Kim, Yeon-Jeong, Kim, Yun-Sun, Ko, Hyun-Jeong, Kang, Chang-Yuil
Formato: Texto
Lenguaje:English
Publicado: The Korean Association of Immunologists 2010
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902672/
https://www.ncbi.nlm.nih.gov/pubmed/20631881
http://dx.doi.org/10.4110/in.2010.10.3.104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902672/
https://www.ncbi.nlm.nih.gov/pubmed/20631881
http://dx.doi.org/10.4110/in.2010.10.3.104

Ejemplares similares